23, 8:48 PM		parison of Age-related Macular Degener	you think!		
	NIH) U.S. Natio	onal Library of Medicine Frials.gov		Find Studies ▼ About Studies ▼ Submit Studies ▼ Resources ▼ About Site ▼ <u>PRS Login</u>	
	Comparison o	of Age-related Macular Degeneration Treatments T	rials Lucentis-Avastin Trial		
A The sa details.		y of this study is the responsibility of the study sponsor and inve	stigators. Listing a study does not mean it has been evaluated b	y the U.S. Federal Government. Read o	ur <u>disclaimer</u> for
alTrials.gov Identifie	er: NCT00593450				
t Posted	/ 15, 2008 August 30, 2012				
w this study on Beta	a.ClinicalTrials.gov				
University of Penns	ute (NEI) d by (Responsible Party):				
y Description f Summary	abular View Study		l unantis nn a fivarl scharlula. Avastin nn a fivarl scharlula. I unar	Go to [
y Description If Summary he purpose of the st	itudy is to evaluate the re visit is being conducted i	lative efficacy and safety of treatment of neovascular AMD with n 2014 to gather information on long term outcomes.	Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucer	tis on a variable schedule, and Avastin	
y Description of Summary The purpose of the st	study is to evaluate the re	lative efficacy and safety of treatment of neovascular AMD with n 2014 to gather information on long term outcomes.	Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucer Intervention/treatment ① Drug ranibizumab		
ly Description ef Summary The purpose of the st A five year follow-up to	study is to evaluate the re visit is being conducted i <u>Condition or disease</u>	lative efficacy and safety of treatment of neovascular AMD with n 2014 to gather information on long term outcomes.	Intervention/treatment O	tis on a variable schedule, and Avastin	
ly Description of Summary The purpose of the st A five year follow-up to tailed Description Age related macular of affected by the advan succentis@ is the most o Lucentis@. n addition, previous s purden to patients as Donly a single eye in e	study is to evaluate the re visit is being conducted i <u>Condition or disease 0</u> Age Related Macular D degeneration (AMD) is the need stage of AMD. st effective treatment for revaluating intravitreal Ava studies do not answer th s well as to reduce the ov each patient was analyzed	lative efficacy and safety of treatment of neovascular AMD with n 2014 to gather information on long term outcomes. egeneration ne leading cause of severe vision loss in people over the age of neovascular AMD studied to date. Bevacizumab (Avastin®) and astin® for the treatment of CNV. Given its molecular similarity to e question of whether a reduced dosing schedule is as effective erall cost of therapy. ed.	Intervention/treatment () Drug ranibizumab	tis on a variable schedule, and Avastin Phase Q Phase 3 1.8 million people in the US currently ha wing the encouraging clinical trial result has been considerable. Avastin@ has n on clinical response has the potential to	ve one or both eyes s with Lucentis®, se ot been evaluated re
by Description of Summary The purpose of the st A five year follow-up of tailed Description Age related macular affected by the advan Lucentis® is the most investigators began er to Lucentis®. In addition, previous s burden to patients as Only a single eye in er At the five year follow	tudy is to evaluate the re visit is being conducted i <u>Condition or disease Q</u> Age Related Macular D Age Related Macular D degeneration (AMD) is ti nced stage of AMD. t effective treatment for evaluating intravitreal Av studies do not answer th s well as to reduce the ov each patient was analyze w-up visit, the subjects wi	lative efficacy and safety of treatment of neovascular AMD with n 2014 to gather information on long term outcomes. legeneration ne leading cause of severe vision loss in people over the age of neovascular AMD studied to date. Bevacizumab (Avastin®) and astin® for the treatment of CNV. Given its molecular similarity to e question of whether a reduced dosing schedule is as effective erall cost of therapy. ed.	Intervention/treatment ① Drug ranibizumab Drug bevacizumab 65 in the United States and other Western countries. More than Lucentis® are derived from the same monoclonal antibody. Folk Lucentis, its low cost, and its availability, the interest in Avastin® as a fixed schedule of monthly injections. Treatment dependent	tis on a variable schedule, and Avastin Phase Q Phase 3 1.8 million people in the US currently ha wing the encouraging clinical trial result has been considerable. Avastin@ has n on clinical response has the potential to	ve one or both eyes s with Lucentis®, se ot been evaluated re reduce the treatmen
ly Description ef Summary The purpose of the st A five year follow-up of tailed Description Age related macular of affected by the advan uccentis@ is the most nuestigators began et o Lucentis@ is the most n	tudy is to evaluate the re visit is being conducted i <u>Condition or disease</u> Age Related Macular D Age Related Macular D Age Related Macular D state of the state of the state studies do not answer the swell as to reduce the ov each patient was analyze w-up visit, the subjects with <u>Study Type</u> <u>Actual Enrollment</u> <u>Allocation:</u> Intervention Model: <u>Primary Purpose</u> :	lative efficacy and safety of treatment of neovascular AMD with n 2014 to gather information on long term outcomes. egeneration the leading cause of severe vision loss in people over the age of neovascular AMD studied to date. Bevacizumab (Avastin®) and astin® for the treatment of CNV. Given its molecular similarity to e question of whether a reduced dosing schedule is as effective erall cost of therapy. ed. Il undergo the same examinations and procedures as in the origin Interventional (Clinical Trial) 1208 participants Randomized Parallel Assignment Triple (Care Provider, Investigator, Outcomes Assessor) Treatment Comparison of Age-related Macular Degeneration Treatments February 2008 December 2010	Intervention/treatment ① Drug ranibizumab Drug bevacizumab 65 in the United States and other Western countries. More than Lucentis® are derived from the same monoclonal antibody. Folk Lucentis, its low cost, and its availability, the interest in Avastin8 as a fixed schedule of monthly injections. Treatment dependent inal study; however, the five year follow-up visit deos not involve	tis on a variable schedule, and Avastin Phase 0 Phase 3 1.6 million people in the US currently ha wing the encouraging clinical trial result has been considerable. Avastin® has no on clinical response has the potential to any study treatment.	ve one or both eyes s with Lucentis®, se ot been evaluated re reduce the treatmen
ly Description of Summary The purpose of the st A five year follow-up of tailed Description Age related macular of fifected by the advan uccentis@. In addition, previous a survestigators began et o Lucentis@. In addition, previous a Survestigators began et addition, previous a Survestigators began et addition, previous a Survestigators began et addition, previous a Survestigators began et addition, previous a Age related macular of Age related macular of addition, previous a Age related macular of Age rel	tudy is to evaluate the re visit is being conducted i <u>Condition or disease @</u> Age Related Macular D degeneration (AMD) is ti noed stage of AMD. at effective treatment for r evaluating intravitreal Auc studies do not answer th s well as to reduce the ov each patient was analyze w-up visit, the subjects wi <u>Study Type @</u> : Actual <u>Enrollment @</u> : Allocation: Intervention Model: Masking: Primary Purpose: Official Title: ual <u>Study Star Date @</u> :	lative efficacy and safety of treatment of neovascular AMD with n 2014 to gather information on long term outcomes. legeneration ne leading cause of severe vision loss in people over the age of neovascular AMD studied to date. Bevacizumab (Avastin®) and ustin® for the treatment of CNV. Given its molecular similarity to e question of whether a reduced dosing schedule is as effective erall cost of therapy. I undergo the same examinations and procedures as in the origination Interventional (Clinical Trial) 1208 participants Randomized Parallel Assignment Triple (Care Provider, Investigator, Outcomes Assessor) Treatment Comparison of Age-related Macular Degeneration Treatments February 2008 December 2010 April 2015	Intervention/treatment ① Drug ranibizumab Drug bevacizumab 65 in the United States and other Western countries. More than Lucentis® are derived from the same monoclonal antibody. Folk Lucentis, its low cost, and its availability, the interest in Avastin8 as a fixed schedule of monthly injections. Treatment dependent inal study; however, the five year follow-up visit deos not involve	tis on a variable schedule, and Avastin Phase 0 Phase 3 1.6 million people in the US currently ha wing the encouraging clinical trial result has been considerable. Avastin® has no on clinical response has the potential to any study treatment.	ve one or both eyes s with Lucentis®, se ot been evaluated re reduce the treatmen
dy Description ief Summary The purpose of the st A five year follow-up of the purpose of the st A five year follow-up of the purpose of the st a file de description Age related macular of affected by the advan Lucentis® is the most investigators began et to Lucentis®. In addition, previous s burden to patients as Only a single eye in et At the five year follow dy Design Actual <u>Prima</u> Actual <u>Stur</u> Resource links prov	tudy is to evaluate the re visit is being conducted i <u>Condition or disease @</u> Age Related Macular D Age Related Macular D as effective treatment for r evaluating intravitreal Auc studies do not answer th is well as to reduce the ov each patient was analyze w-up visit, the subjects wi <u>Study Type @</u> : <u>Actual Enrollment @</u> : <u>Allocation</u> : Intervention Model: <u>Masking:</u> <u>Primary Purpose:</u> <u>Official Title:</u> ual <u>Study Stan Date @</u> : wided by the National L	lative efficacy and safety of treatment of neovascular AMD with n 2014 to gather information on long term outcomes. legeneration ne leading cause of severe vision loss in people over the age of neovascular AMD studied to date. Bevacizumab (Avastin®) and ustin® for the treatment of CNV. Given its molecular similarity to e question of whether a reduced dosing schedule is as effective erall cost of therapy. I undergo the same examinations and procedures as in the origination Interventional (Clinical Trial) 1208 participants Randomized Parallel Assignment Triple (Care Provider, Investigator, Outcomes Assessor) Treatment Comparison of Age-related Macular Degeneration Treatments February 2008 December 2010 April 2015	Intervention/treatment ① Drug ranibizumab Drug bevacizumab 65 in the United States and other Western countries. More than Lucentis® are derived from the same monoclonal antibody. Folk Lucentis, its low cost, and its availability, the interest in Avastin8 as a fixed schedule of monthly injections. Treatment dependent inal study; however, the five year follow-up visit deos not involve	tis on a variable schedule, and Avastin Phase ① Phase ① Phase 3 1.8 million people in the US currently ha wing the encouraging clinical trial result has been considerable. Avastin® has n on clinical response has the potential to any study treatment. Go to	ve one or both eyes s with Lucentis®, se ot been evaluated re reduce the treatmen
dy Description ief Summary The purpose of the st A five year follow-up of tailed Description Age related macular Age related macular affected by the advan Lucentis® is the most investigators began et to Lucentis®. In addition, previous st burden to patients as Only a single eye in e At the five year follow dy Design Actual Stur Resource links prov MedimePlus Genetic	tudy is to evaluate the re visit is being conducted i <u>Condition or disease @</u> Age Related Macular D Age Related Macular D as effective treatment for r evaluating intravitreal Auc studies do not answer th is well as to reduce the ov each patient was analyze w-up visit, the subjects wi <u>Study Type @</u> : <u>Actual Enrollment @</u> : <u>Allocation</u> : Intervention Model: <u>Masking:</u> <u>Primary Purpose:</u> <u>Official Title:</u> ual <u>Study Stan Date @</u> : wided by the National L	lative efficacy and safety of treatment of neovascular AMD with n 2014 to gather information on long term outcomes. eggeneration the leading cause of severe vision loss in people over the age of neovascular AMD studied to date. Bevacizumab (Avastin®) and astin® for the treatment of CNV. Given its molecular similarity to e question of whether a reduced dosing schedule is as effective erall cost of therapy. ed. Il undergo the same examinations and procedures as in the origin Interventional (Clinical Trial) 1208 participants Randomized Parallel Assignment Triple (Care Provider, Investigator, Outcomes Assessor) Treatment Comparison of Age-related Macular Degeneration Treatments February 2008 December 2010 April 2015 ibrary of Medicine lated macular degeneration	Intervention/treatment ① Drug ranibizumab Drug bevacizumab 65 in the United States and other Western countries. More than Lucentis® are derived from the same monoclonal antibody. Folk Lucentis, its low cost, and its availability, the interest in Avastin8 as a fixed schedule of monthly injections. Treatment dependent inal study; however, the five year follow-up visit deos not involve	tis on a variable schedule, and Avastin Phase ① Phase ① Phase 3 1.8 million people in the US currently ha wing the encouraging clinical trial result has been considerable. Avastin® has n on clinical response has the potential to any study treatment. Go to	ve one or both eyes s with Lucentis®, se ot been evaluated re reduce the treatmen
dy Description ief Summary The purpose of the st A five year follow-up of the purpose of the st A five year follow-up of the purpose of the st affected by the advant Lucentis® is the most investigators began et to Lucentis®. In addition, previous st burden to patients as Only a single eye in et At the five year follow dy Design Actual <u>Prima</u> Actual <u>Prima</u> Actual <u>Stur</u> Resource links prov <u>MedlinePlus related f</u>	tudy is to evaluate the re visit is being conducted i <u>Condition or disease @</u> Age Related Macular D Age Related Macular D the second stage of AMD, st effective treatment for n evaluating intravitreal Ava- studies do not answer the swell as to reduce the ov each patient was analyze w-up visit, the subjects wi <u>Study Type @</u> : <u>Altical Enrollment @</u> : <u>Altical Enrollment @</u> : <u>Altical Tire:</u> Washing: Primary Purpose: <u>Official Title:</u> widy Start Date @: ary Completion Date @ : wided by the National L <u>Constructions:</u> <u>Age-re</u>	lative efficacy and safety of treatment of neovascular AMD with n 2014 to gather information on long term outcomes. egeneration the leading cause of severe vision loss in people over the age of neovascular AMD studied to date. Bevacizumab (Avastin®) and astin® for the treatment of CNV. Given its molecular similarity to e question of whether a reduced dosing schedule is as effective erall cost of therapy. ed. Il undergo the same examinations and procedures as in the origin Interventional (Clinical Trial) 1208 participants Randomized Parallel Assignment Triple (Care Provider, Investigator, Outcomes Assessor) Treatment Comparison of Age-related Macular Degeneration Treatments February 2008 December 2010 April 2015 ibrary of Medicine lated macular degeneration reation	Intervention/treatment ① Drug ranibizumab Drug bevacizumab 65 in the United States and other Western countries. More than Lucentis® are derived from the same monoclonal antibody. Folk Lucentis, its low cost, and its availability, the interest in Avastin8 as a fixed schedule of monthly injections. Treatment dependent inal study; however, the five year follow-up visit deos not involve	tis on a variable schedule, and Avastin Phase ① Phase ① Phase 3 1.8 million people in the US currently ha wing the encouraging clinical trial result has been considerable. Avastin® has n on clinical response has the potential to any study treatment. Go to	ve one or both eyes s with Lucentis®, se ot been evaluated re reduce the treatmen

Arms and Interventions

DOCKET A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

Go to 💌

3/13/23, 8:48 PM

Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial - Full Text View - ClinicalTrials.gov

Arm	Intervention/treatment O
Active Comparator 1	Drug ranibizumab
Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks	• 0.5 mg (0.05 mL)intravitreal injection
or to variable dosing.	Other Name: Lucentis
Experimental 2	Drug bevacizumab
Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or	• 1.25 mg (0.05 mL)intravitreal injection
to variable dosing.	Other Name: Avastin
Experimental 3	Drug ranibizumab
Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment	• 0.5 mg (0.05 mL)intravitreal injection
based on signs of lesion activity.	Other Name: Lucentis
Experimental 4	Drug bevacizumab
Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment	• 1.25 mg (0.05 mL intravitreal injection
based on signs of lesion activity.	Other Name: Avastin

Outcome Measures

Primary Outcome Measures @

1. Change From Baseline in Visual-acuity Score (Continuous) [Time Frame: Baseline and 1 Year]

Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly. The VA score change is the difference of the VA score at 1 Year and the VA score at baseline.

In this study, the outcome VA score change is ranged from -71 to 52, with the higher VA score change the better visual acuity improvement.

Secondary Outcome Measures ()

- 1. Change From Baseline Visual-acuity Score (Frequency) [Time Frame: Baseline and 1 Year]
- 2. Visual-acuity Score and Snellen Equivalent (Frequency) [Time Frame: at 1 Year]
- 3. Visual-acuity Score and Snellen Equivalent (Continuous) [Time Frame: at 1 Year]
 - Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly.

In this study, the outcome VA score is ranged from 0 to 97, with the higher score the better visual acuity.

4. Number of Treatments [Time Frame: 1 Year]

Cumulative over the 1 year of trial

5. Average Cost of Drug/Patient [Time Frame: at 1 Year]

- 6. Total Thickness at Fovea [Time Frame: at 1 Year]
- 7. Total Thickness Change From Baseline at Fovea [Time Frame: Baseline and 1 Year]
- 8. Retinal Thickness Plus Subfoveal-fluid Thickness at Fovea [Time Frame: at 1 Year]
- 9. Retinal Thickness Plus Subfoveal-fluid Thickness Change From Baseline at Fovea [Time Frame: Baseline and 1 Year]
- 10. Fluid on Optical Coherence Tomography [Time Frame: at 1 Year]
- 11. Dye Leakage on Angiogram [Time Frame: at 1 Year]
- 12. Area of Lesion [Time Frame: at 1 Year]
- 13. Area of Lesion Change From Baseline [Time Frame: Baseline and 1 Year]
- 14. Change in Systolic Blood Pressure From Baseline [Time Frame: Baseline and 1 Year]
- 15. Change in Diastolic Blood Pressure From Baseline [Time Frame: Baseline and 1 Year]

Eligibility Criteria

Go to 💌

NIH

Go to 💌

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies,

Ages Eligible for Study: 50 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No

Accepts meaniny voluntee

Criteria Inclusion Criteria:

- Active, subfoveal choroidal neovascularization (CNV)
- Fibrosis < 50% of total lesion area
- Visual acuity (VA) 20/25-20/320
- Age ≥ 50 yrs
- Age 2.00 yrs
- + At least 1 drusen (>63 μ) in either eye or late AMD in fellow eye
- Exclusion Criteria:
- · Previous treatment for CNV in study eye
- Other progressive retinal disease likely to compromise VA
- · Contraindications to injections with Lucentis or Avastin

Contacts and Locations

DOCKET

Δ

Go to 💌

LARM Find authenticated court documents without watermarks at docketalarm.com

Please refer to this stu	is study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
	udy by its ClinicalTrials.gov identifier (NCT number): NCT00593450
ocations	
Show 59 study location	xns
ponsors and Collaborator	78
University of Pennsylva	ania
National Eye Institute (I	
nvestigators	
Study Chair:	Daniel F Martin, MD The Cleveland Clinic
Study Chair:	Stuart L Fine, MD Study Vice-Chair, University of Pennsylvania
Study Director:	Maureen G Maguire, PhD Director of Coordinating Center, University of Pennsylvania
Study Director:	Glenn Jaffe, MD Director of OCT Reading Center, Duke University
Principal Investigator:	Juan E Grunwald, MD Principal Investigator of Photography Reading Center, Universisty of Pennsylvania
re Information	Goto
dditional Information:	
Click here for more infr	formation about this study: Comparison of AMD Treatments Trials (CATT) 199
NEI Clinical Studies Da	
HEI OIIIIdal Studies De	
ublications of Results:	
	p; Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19;384(20):1897-908. doi: 1873. Epub 2011 Apr 28.
	lated Macular Degeneration Treatments Trials (CATT) Research Group; Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Ranibizumab and bevacizumab for treatm lated macular degeneration: two-year results. Ophthalmology. 2012 Jul; 119(7):1388-98. doi: 10.1018/j.ophtha.2012.03.053. Epub 2012 May 1.
	E, Ying GS, Pistilli M, Maguire MG, Alexander J, Whittook-Martin R, Parker CR, Sepielli K, Blodi BA, Martin DF; CATT Research Group. Photographic assessment of baseline fundus morphologic features in the elated Macular Degeneration Treatments Trials. Ophthalmology. 2012 Aug;119(8):1834-41. doi: 10.1016/j.ophtha.2012.02.013. Epub 2012 Apr 17.
Martia DE Marcina M	
Martin DF, Maguire MG	G, Fine SL. Bevaoizumab: not as good with more adverse reactions? Response. Clin Exp Ophthalmol. 2011 Sep-Oct;39(7):718-20. doi: 10.1111/j.1442-9071.2011.02703.x. No abstract available.
Cheung CM, Wong TY.	.f. Ranibizumab and bevacizumab for AMD. N Engl J Med. 2011 Dec 8;365(23):2237; author reply 2237. doi: 10.1056/NEJMc1107895. No abstract available.
	Stinnett SS, Heydary CS, Burns R, Jaffe GJ; CATT Research Group. Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. Dec;119(12):2549-57. doi: 10.1016/j.ophtha.2012.06.040. Epub 2012 Aug 28.
	guire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Baseline predictors for one-year ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013 Jan; 120(1):122-0. doi: 10.1018/j.ophtha.2012.07.042. Epub 2012 Oct 6.
	S, Pauer GJT, Sturgil-Short GM, Huang J, Callanan DG, Kim IK, Klein ML, Maguire MG, Martin DF; Comparison of AMD Treatments Trials Research Group. Pharmacogenetics for genes associated with age-related in the Comparison of AMD Treatments Trials (CATT). Ophthalmology. 2013 Mar; 120(3):593-599. doi: 10.1018/j.ophtha.2012.11.037. Epub 2013 Jan 18.
Jaffe GJ. Martin DF. To	
	oth CA, Daniel E, Maguire MG, Ying GS, Grunwald JE, Huang J: Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the comparison of age
	oth CA, Daniel E, Maguire MG, Ying GS, Grunwald JE, Huang J; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the comparison of age neration treatments trials. Ophthalmology. 2013 Sep;120(0):1880-70. doi: 10.1010/j.ophtha.2013.01.073. Epub 2013 May 1.
related macular degenerics Maguire MG, Daniel E,	
related macular degeneric Maguire MG, Daniel E, Group). Incidence of ch Daniel E, Toth CA, Gru	neration treatments trials. Ophthalmology. 2013 Sep;120(0):1880-70. doi: 10.1016/i.ophtha.2013.01.073. Epub 2013 May 1. ; Shah AR, Grunwald JE, Hagstrom SA, Avery RL, Huang J, Martin RW, Rolh DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research shoroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013 Oct; 120(10):2035-41. doi: 10.1018/i.ophtha.2013.03.017. Epub 2013 May 1.
related macular degener Maguire MG, Daniel E, Group). Incidence of et Daniel E, Toth CA, Gru age-related macular de Grunwald JE, Daniel E	neration treatments trials. Ophthalmology. 2013 Sep;120(9):1880-70. doi: 10.1016/i.ophtha.2013.01.073. Epub 2013 May 1. Exact Section
related macular degener Maguire MG, Daniel E, Group). Incidence of et Daniel E, Toth CA, Gru age-related macular de Grunwald JE, Daniel E	neration treatments trials. Ophthalmology. 2013 Sep;120(9):1880-70. doi: 10.1016/i.ophtha.2013.01.073. Epub 2013 May 1. i, Shah AR, Grunwald JE, Hagstrom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research ichoroidal neovascularization in the fellow eve in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013 Oct;120(10):2035-41. doi: 10.1016/i.ophtha.2013.03.017. Epub 2013 May unwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying GS, Hagstrom SA, Winter K, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of scar in the comparison egeneration treatments trials. Ophthalmology. 2014 Mar;121(3):858-86. doi: 10.1016/i.ophtha.2013.10.019. Epub 2013 Dec 4.
related macular degen Maguire MG, Daniel E, Group). Incidence of ch Daniel E, Toth CA, Gru age-related macular de Grunwald JE, Daniel E degeneration treatment Hagstrom SA, Ying GS	neration treatments trials. Ophthalmology. 2013 Sep;120(9):1880-70. doi: 10.1016/i.ophtha.2013.01.073. Epub 2013 May 1. Shah AR, Grunwald JE, Hagstrom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research shoroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013 Oct;120(10):2035-41. doi: 10.1018/i.ophtha.2013.03.017. Epub 2013 May unwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying GS, Hagstrom SA, Winter K, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of scar in the comparisor legeneration treatments trials. Ophthalmology. 2014 Mar;121(3):856-86. doi: 10.1018/i.ophtha.2013.10.019. Epub 2013 Dec 4. E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF; CATT Research Group. Risk of geographic atrophy in the comparison of age-related macular nts trials. Ophthalmology. 2014 Jan;121(1):150-161. doi: 10.1018/i.ophtha.2013.08.015. Epub 2013 Sep 29. S, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. VEGFA and VEGFR2 gene polymorphisms and
related macular degen Maguire MG, Daniel E, Group). Incidence of ch Daniel E, Toth CA, Gru age-related macular de Grunwald JE, Daniel E degeneration treatment Hagstrom SA, Ying GS	neration treatments trials. Ophthalmology. 2013 Sep;120(9):1880-70. doi: 10.1016/i.ophtha.2013.01.073. Epub 2013 May 1. Expand AR, Grunwald JE, Hagstrom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research thoroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013 Oct;120(10):2035-41. doi: 10.1016/i.ophtha.2013.03.017. Epub 2013 May unwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying GS, Hagstrom SA, Winter K, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of scar in the comparison egeneration treatments trials. Ophthalmology. 2014 Mar;121(3):656-86. doi: 10.1016/i.ophtha.2013.01.019. Epub 2013 Dec 4. E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF; CATT Research Group. Risk of geographic atrophy in the comparison of age-related macular the trials. Ophthalmology. 2014 Jan;121(1):150-161. doi: 10.1016/i.ophtha.2013.08.015. Epub 2013 Sep 20.
related macular degen Maguire MG, Daniel E, Group). Incidence of ch Daniel E, Toth CA, Gru age-related macular de Grunwald JE, Daniel E degeneration treatment Hagstrom SA, Ying GS response to anti-vasou Kim BJ, Ying GS, Huar	terration treatments trials. Ophthalmology. 2013 Sep;120(9):1880-70. doi: 10.1016/i.ophtha.2013.01.073. Epub 2013 May 1. Expand AR, Grunwald JE, Hagstrom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research theroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013 Oct;120(10):2035-41. doi: 10.1016/i.ophtha.2013.03.017. Epub 2013 May unwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying GS, Hagstrom SA, Winter K, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013 Oct;120(10):2035-41. doi: 10.1016/i.ophtha.2013.03.017. Epub 2013 May unwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying GS, Hagstrom SA, Winter K, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of scar in the comparison egeneration treatments trials. Ophthalmology. 2014 Mar;121(3):056-08. doi: 10.1016/i.ophtha.2013.10.019. Epub 2013 Dec 4. E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF; CATT Research Group. Risk of geographic atrophy in the comparison of age-related macular trials. Ophthalmology. 2014 Jan;121(1):180-101. doi: 10.1016/i.ophtha.2013.08.015. Epub 2013 Sep 29. S, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. VEGFA and VEGFR2 gene polymorphisms and lar endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). JAMA Ophthalmol. 2014 May;132(5):521-7. doi: 10.10101/jamaophthalmol.2014.109.
related macular degen- Maguire MG, Daniel E, Group). Incidence of ch Daniel E, Toth CA, Gru age-related macular de Grunwald JE, Daniel E degeneration treatment Hagstrom SA, Ying GS response to anti-vasou Kim BJ, Ying GS, Huar 10.1016/j.ajo.2014.04.05	terration treatments trials. Ophthalmology. 2013 Sep;120(9):1880-70. doi: 10.1016/i.ophtha.2013.01.073. Epub 2013 May 1. i. Shah AR, Grunwald JE, Hagstrom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research theroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013 Oct;120(10):2035-41. doi: 10.1016/i.ophtha.2013.03.017. Epub 2013 May unwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying GS, Hagstrom SA, Winter K, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of scar in the comparison is generation treatments trials. Ophthalmology. 2013 Oct;120(10):2035-41. doi: 10.1016/i.ophtha.2013.03.017. Epub 2013 May unwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying GS, Hagstrom SA, Winter K, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of scar in the comparison is generation treatments trials. Ophthalmology. 2014 Mar;121(3):856-86. doi: 10.1016/j.ophtha.2013.10.019. Epub 2013 Dec 4. E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF; CATT Research Group. Risk of geographic atrophy in the comparison of age-related macular rist trials. Ophthalmology. 2014 Jan;121(1):150-101. doi: 10.1010/j.ophtha.2013.08.015. Epub 2013 Sep 29. S, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. VEGFA and VEGFR2 gene polymorphisms and ular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). JAMA Ophthalmol. 2014 May;132(5):521-7. doi: 10.1001/jamaophthalmol.2014.109. ng J, Levy NE, Maguire MG; CATT Research Group. Sporadic visual acuity loss in the Comparison of Age-Related Macula
related macular degen Maguire MG, Daniel E, Group). Incidence of ch Daniel E, Toth CA, Gru age-related macular de Grunwald JE, Daniel E degeneration treatmen Hagstrom SA, Ying GS response to anti-vascu Kim BJ, Ying GS, Huar 10.1016/j.ajo.2014.04.1 Folgar FA, Jaffe GJ, Yin macular degeneration	 heration treatments trials. Ophthalmology. 2013 Sep;120(9):1880-70. doi: 10.1016/i.ophtha.2013.01.073. Epub 2013 May 1. Shah AR, Grunwald JE, Hagstrom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research theoroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013 Oct;120(10):2035-41. doi: 10.1018/i.ophtha.2013.03.017. Epub 2013 May: unwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying GS, Hagstrom SA, Winter K, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of scar in the comparisor egeneration treatments trials. Ophthalmology. 2014 Mar;121(3):856-86. doi: 10.1018/i.ophtha.2013.10.019. Epub 2013 Dec 4. Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF; CATT Research Group. Risk of geographic atrophy in the comparison of age-related macular nest trials. Ophthalmology. 2014 Jan;121(1):150-101. doi: 10.1018/i.ophtha.2013.08.015. Epub 2013 Sep 29. S, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. VEGFA and VEGFR2 gene polymorphisms and ular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). JAMA Ophthalmol. 2014 May;132(5):521-7. doi: 10.10101/jamaophthalmol.2014.109. Ing J, Levy NE, Maguire MG; CATT Research Group. Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol. 2014 Jul;158(1):128-135.e10. d. 0.014. Epub 2014 Apr 13. Ting GS, Maguire MG, Toth CA; Comparison of Age-Related Macular Degeneration Group. Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol.
related macular degen Maguire MG, Daniel E, Group). Incidence of ch Daniel E, Toth CA, Gru age-related macular de Grunwald JE, Daniel E degeneration treatment Hagstrom SA, Ying GS response to anti-vascu Kim BJ, Ying GS, Huar 10.1016/j.ajo.2014.04.01 Folgar FA, Jaffe GJ, Yin macular degeneration 1 Ying GS, Kim BJ, Magi	 heration treatments trials. Ophthalmology. 2013 Sep;120(9):1880-70. doi: 10.1016/i.ophtha.2013.01.073. Epub 2013 May 1. Shah AR, Grunwald JE, Hagstrom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research theroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013 Oct;120(10):2035-41. doi: 10.1018/i.ophtha.2013.03.017. Epub 2013 May. unwald JE, Jalfe GJ, Martin DF, Fine SL, Huang J, Ying GS, Hagstrom SA, Winter K, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of scar in the comparisor egeneration treatments trials. Ophthalmology. 2014 Mar;121(3):858-86. doi: 10.1016/j.ophtha.2013.01.019. Epub 2013 Dec 4. Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF; CATT Research Group. Risk of geographic atrophy in the comparison of age-related macular this trials. Ophthalmology. 2014 Jan;121(1):150-161. doi: 10.1016/j.ophtha.2013.08.015. Epub 2013 Sep 29. S. Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. VEGFA and VEGFR2 gene polymorphisms and ular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). JAMA Ophthalmol. 2014 May;132(5):521-7. doi: 10.10101/j.amaophthalmol.2014.109. Ing J, Levy NE, Maguire MG; CATT Research Group. Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol. 2014 Jul;158(1):128-135.e10. d. 004. Epub 2014 Apr 13. Ing GS, Maguire MG, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol. 2014 Jul;158(1):128-135.e10. d. 004. Epub 2014 Apr 13.<!--</td-->
related macular degen Maguire MG, Daniel E, Group). Incidence of cf Daniel E, Toth CA, Gru age-related macular de Grunwald JE, Daniel E degeneration treatmen Hagstrom SA, Ying GS response to anti-vascu Kim BJ, Ying GS, Huar 10.1016/j.ajo.2014.04.01 Folgar FA, Jaffe GJ, Yin macular degeneration 1 Ying GS, Kim BJ, Magg treatments trials. JAMAP Gewaihy DY, Grunwald	 heration treatments trials. Ophthalmology. 2013 Sep;120(9):1880-70. doi: 10.1016/i.ophtha.2013.01.073. Epub 2013 May 1. i. Shah AR, Grunwald JE, Hagstrom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research throidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013 Oct;120(10):2035-41. doi: 10.1016/i.ophtha.2013.03.017. Epub 2013 May unwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying GS, Hagstrom SA, Winter K, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of scar in the comparison is generation treatments trials. Ophthalmology. 2014 Mar;121(3):856-86. doi: 10.1016/j.ophtha.2013.01.019. Epub 2013 Dec 4. E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF; CATT Research Group. Risk of geographic atrophy in the comparison of age-related macular this trials. Ophthalmology. 2014 Jan;121(1):150-161. doi: 10.1016/j.ophtha.2013.08.015. Epub 2013 Sep 29. S, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Research Group. VEGFA and VEGFR2 gene polymorphisms and ular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). JAMA Ophthalmol. 2014 May;132(5):521-7. doi: 10.1001/jamaophthalmol.2014.109. Ing GS, Maguire MG; CATT Research Group. Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol. 2014 Jul;158(1):128-135.e10. doi: 0.004. Epub 2014 Apr 13. Ing GS, Maguire MG, Toth CA, Comparison of Age-Related Macular Degeneration Treatments Trials. Coherence tomography assessments in the comparison of age-related treatments trials. Ophthalmology. 2014 Ac
related macular degen Maguire MG, Daniel E, Group). Incidence of cf Daniel E, Toth CA, Gru age-related macular de Grunwald JE, Daniel E degeneration treatmen Hagstrom SA, Ying GS response to anti-vascu Kim BJ, Ying GS, Huar 10.1016/j.ajo.2014.04.01 Folgar FA, Jaffe GJ, Yir macular degeneration 1 Ying GS, Kim BJ, Magg treatments trials. JAMA Gewaily DY, Grunwald Ophthalmol. 2014 Sep. Lee JY, Folgar FA, Mag	 heration treatments trials. Ophthalmology. 2013 Sep;120(9):1880-70. doi: 10.1016/j.ophtha.2013.01.073. Epub 2013 May 1. ii, Shah AR, Grunwald JE, Hagstrom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013 Oct;120(10):2035-41. doi: 10.1016/j.ophtha.2013.03.017. Epub 2013 May unwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying GS, Hagstrom SA, Winter K, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of scar in the comparison generation treatments trials. Ophthalmology. 2014 Mar;121(3):656-68. doi: 10.1016/j.ophtha.2013.10.019. Epub 2013 Dec 4. E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF; CATT Research Group. Risk of geographic atrophy in the comparison of age-related macular that trials. Ophthalmology. 2014 Jan;121(1):150-161. doi: 10.1016/j.ophtha.2013.08.015. Epub 2013 Sep 29. S, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. VEGFA and VEGFR2 gene polymorphisms and ular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). JAMA Ophthalmol. 2014 May;132(6):521-7. doi: 10.1001/jamaophthalmol.2014.101.128(1):128-135.e10. doi: 10.1016/j.ophtha.2013.04.019. Epub 2014 May 15. Ing GS, Maguire MG, Toth CA; Comparison of Age-Related Macular Degeneration Group. Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration Treatments Trials Research Group. Social coherence tomography assessments in the comparison of age-related macular degeneration A Ophthalmology. 2014 Apr 13.
related macular degen Maguire MG, Daniel E, Group). Incidence of cf Daniel E, Toth CA, Gru age-related macular de Grunwald JE, Daniel E degeneration treatment Hagstrom SA, Ying GS response to anti-vascu Kim BJ, Ying GS, Huar 10.1016/j.ajo.2014.04.01 Folgar FA, Jaffe GJ, Yi macular degeneration 1 Ying GS, Kim BJ, Magg treatments trials. JAMP Gewaily DY, Grunwald Ophthalmol. 2014 Sep. Lee JY, Folgar FA, Mag Dec;121(12):2423-31.1 Moja L, Lucenteforte E	 Beration treatments trials. Ophthalmology. 2013 Sep;120(9):1860-70. doi: 10.1016/j.ophtha.2013.0173. Epub 2013 May 1. Shah AR, Grunwald JE, Hagstrom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research throoidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013 Oct;120(10):2035-41. doi: 10.1016/j.ophtha.2013.03.017. Epub 2013 May unwald JE, Hagstrom SA, Winter K, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of scar in the comparison degeneration treatments trials. Ophthalmology. 2014 Mar;121(3):856-86. doi: 10.1016/j.ophtha.2013.10.019. Epub 2013 Dec 4. Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF; CATT Research Group. Risk of geographic atrophy in the comparison of age-related macular ts trials. Ophthalmology. 2014 Jan;121(1):150-161. doi: 10.1016/j.ophtha.2013.08.015. Epub 2013 Sep 22. Pauer GJ, Sturgil-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. VEGFA and VEGFR2 gene polymorphisms and alar endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). JAMA Ophthalmol. 2014 May;132(5):521-7. doi: 10.1010/ijamaophthalmol.2014.100. Ing J, Levy NE, Maguire MG; Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol. 2014 Jul;158(1):128-135.e10. d. 0.04. Epub 2014 Apr 13. Ing GS, Maguire MG, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. 2014 Agr;132(8):915-21. doi: 10.1001/jamaophthalmol.2014.1018/. Ing GS, Maguire MG, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials Research G
related macular degen Maguire MG, Daniel E, Group). Incidence of cf Daniel E, Toth CA, Gru age-related macular de Grunwald JE, Daniel E degeneration treatment Hagstrom SA, Ying GS response to anti-vascu Kim BJ, Ying GS, Huar 10.1016/j.ajo.2014.04.01 Folgar FA, Jaffe GJ, Yi macular degeneration 1 Ying GS, Kim BJ, Magg treatments trials. JAMP Gewaily DY, Grunwald Ophthalmol. 2014 Sep. Lee JY, Folgar FA, Mag Dec;121(12):2423-31.1 Moja L, Lucenteforte E	 heration treatments trials. Ophthalmology. 2013 Sep:120(9):1880-70. doi: 10.1016/i.ophtha.2013.01.073. Epub 2013 May 1. iiii Shah AR, Grunwald JE, Hagstrom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research theoroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013 Oct;120(10):2035-41. doi: 10.1016/i.ophtha.2013.03.017. Epub 2013 May 1. unwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying GS, Hagstrom SA, Winter K, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014 Mar;121(3):666-80. doi: 10.1016/j.ophtha.2013.00.019. Epub 2013 Dec 4. Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF; CATT Research Group. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments Trials (CATT) Research Group. VEGFA and VEGFR2 gene polymorphisms and ular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). Research Group. VEGFA and VEGFR2 gene polymorphisms and ular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). Am J Ophthalmol.2014.100. Ing J, Levy NE, Maguire MG, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol.2014.101;128-135.e10. doi: 0.1001/j.amaophthalmol.2014.001;j.ephtha.2014.04.020. Epub 2014 May 15. Ing GS, Maguire MG, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol.2014.101;j.ephtha.2014.04.020. Epub 2014 May 15. Ing GS, Maguire MG, Huang J, Daniel E, Jaffe GJ, Grunwald JE, Blinder
related macular degen- Maguire MG, Daniel E, Group). Incidence of el Daniel E, Toth CA, Gru age-related macular de Grunwald JE, Daniel E degeneration treatment Hagstrom SA, Ying GS response to anti-vascu Kim BJ, Ying GS, Huar 10.1016/j.ajo.2014.04.01 Folgar FA, Jaffe GJ, Yi macular degeneration 1 Ying GS, Kim BJ, Magu treatments trials. JAMB Gewaily DY, Grunwald Ophthalmol. 2014 Sep. Lee JY, Folgar FA, Mag Dec; 121(12):2423-31.1 Moja L, Lucenteforte E Subtramaniam ML, Virgi Altaweel MM, Daniel E Comparison of Age-relation of Age-relation of Age-relation Model A. Statement Stratement Stra	 seration treatments trials. Ophthalmology. 2013 Sep;120(9):1880-70. doi: 10.1016/i.ophtha.2013.01.073. Epub 2013 May 1. s. Shah AR, Grunwald JE, Hagstom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research hroroidal neovascularization in the fellow yee in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013 Oct;120(10):2035-41. doi: 10.1016/i.ophtha.2013.00.017. Epub 2013 May unwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying GS, Hagstrom SA, Winter K, Maguire MG, Comparison of Age-related Macular Degeneration Treatments Trials. Research Group. Risk of scar in the comparison generation treatments trials. Ophthalmology. 2014 Mar;121(3):565-86. doi: 10.1016/i.ophtha.2013.10.001. Epub 2013 Dec 4. s. Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF; Compa. Risk of geographic atrophy in the comparison of age-related macular tegeneration treatments trials. Ophthalmology. 2014 Jan;121(1):150-161. doi: 10.1016/i.ophtha.2013.00.015. Epub 2013 Sep 29. s. Pauer GJ, Sturgli-Short MGM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. VEGFA and VEGFR2 gene polymorphisms and aliar endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). JAMA Ophthalmol. 2014 May;132(5):521-7. doi: 10.1001/jamaophthalmol.2014.109. ng J, Levy NE, Maguire MG, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol.2014.109. ng GS, Maguire MG, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol.2014.109. ng GS, Maguire MG, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol.2014.1012.
related macular degen Maguire MG, Daniel E, Group). Incidence of ch Daniel E, Toth CA, Gru age-related macular de Grunwald JE, Daniel E degeneration treatmen Hagstrom SA, Ying GS response to anti-vascu Kim BJ, Ying GS, Huar 10.1016/j.ajo.2014.04.1 Folgar FA, Jaffe GJ, Yi macular degeneration 1 Ying GS, Kim BJ, Magy treatments trials. JAMP Geewaily DY, Grunwald Ophthalmol. 2014 Sep. Lee JY, Folgar FA, Mag Dec;121(12):2423-31.1 Moia L, Lucenteforte E Subramanian ML, Virgi Altaweel MM, Daniel E Comparison of Age-reli Ophthalmology. 2015 F	 Interation treatments trials. Ophthalmology. 2013 Sep:120(9):1880-70. doi: 10.1016/j.ophtha.2013.01.073. Epub 2013 May 1. Shah AR, Grunwald JE, Hagstrom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin AA, Batri SJ, Fine SL, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research horoidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013 Oc; 120(10):2054-41. doi: 10.1016/j.ophtha.2013.03.017. Epub 2013 May 1. anwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying GS, Hagstrom SA, Winter K, Maguire MG, Comparison of Age-related Macular Degeneration Treatments Trials (CATT) (21):50-50-50. F. Juang J, Ying GS, Maguire MG, Toh CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF; CATT Research Group. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials (DATT) Research Group. VEGFA and VEGFR2 gene polymorphisms and alar endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT) Research Group. VEGFA and VEGFR2 gene polymorphisms and alar endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). Research Group. VEGFA and VEGFR2 gene polymorphisms and alar endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). Am J Ophthalmol. 2014.109. J. Levy NE, Maguire MG, CATT Research Group. Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol. 2014.001;158(1):128-135.e10. doi: 10.1016/j.jophtha.2014.04.020.Epub 2014 May 15. Ting SS, Maguire MG, Toh CA, Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol. 2014.00;158(1):128-135.e10.001/jamaophthalmal.2014.00;214.00;129.e102.e101.001/jamaophthalmol.2014.00;214.00
related macular degen Maguire MG, Daniel E, Group). Incidence of ch Daniel E, Toth CA, Gru age-related macular de Grunwald JE, Daniel E degeneration treatmen Hagstrom SA, Ying GS response to anti-vasou Kim BJ, Ying GS, Huar 10.1016/j.ajo.2014.04.1 Folgar FA, Jaffe GJ, Yi macular degeneration 1 Ying GS, Kim BJ, Magy treatments trials. JAMA Gewaily DY, Grunwald Ophthalmol. 2014 Seg. Lee JY, Folgar FA, Mag Dec;121(12):242-33.1 Moja L, Lucenteforte E Subramanian ML, Vigj Altaweel MM, Daniel E Comparison of Age-rel Ophthalmology. 2015 F Grunwald JE, Pistilli M,	 seration treatments trials. Ophthalmology. 2013 Sep;120(9):1880-70. doi: 10.1016/i.ophtha.2013.01.073. Epub 2013 May 1. s. Shah AR, Grunwald JE, Hagstom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research hroroidal neovascularization in the fellow yee in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013 Oct;120(10):2035-41. doi: 10.1016/i.ophtha.2013.00.017. Epub 2013 May unwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying GS, Hagstrom SA, Winter K, Maguire MG, Comparison of Age-related Macular Degeneration Treatments Trials. Research Group. Risk of scar in the comparison generation treatments trials. Ophthalmology. 2014 Mar;121(3):565-86. doi: 10.1016/i.ophtha.2013.10.001. Epub 2013 Dec 4. s. Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF; Compa. Risk of geographic atrophy in the comparison of age-related macular tegeneration treatments trials. Ophthalmology. 2014 Jan;121(1):150-161. doi: 10.1016/i.ophtha.2013.00.015. Epub 2013 Sep 29. s. Pauer GJ, Sturgli-Short MGM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. VEGFA and VEGFR2 gene polymorphisms and aliar endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). JAMA Ophthalmol. 2014 May;132(5):521-7. doi: 10.1001/jamaophthalmol.2014.109. ng J, Levy NE, Maguire MG, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol.2014.109. ng GS, Maguire MG, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol.2014.109. ng GS, Maguire MG, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol.2014.1012.

Meredith TA, McCannel CA, Barr C, Doft BH, Peskin E, Maguire MG, Martin DF, Prenner JL; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Postinjection endophthalmitis in the comparison of agerelated macular degeneration treatments trials (CATT). Ophthalmology. 2015 Apr;122(4):817-21. doi: 10.1016/j.ophtha.2014.10.027. Epub 2015 Jan 15.

0./F

DOCKET

Δ

LARM Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

Toth CA, Decross FC, Ying GS, Stinnett SS, Heydary CS, Burns R, Maguire M, Martin D, Jaffe GJ. IDENTIFICATION OF FLUID ON OPTICAL COHERENCE TOMOGRAPHY BY TREATING OPHTHALMOLOGISTS VERSUS A READING CENTER IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS. Retina. 2015 Jul;35(7):1303-14. doi: 10.1097/IAE.000000000000483_

Ciulla TA, Ying GS, Maguire MG, Martin DF, Jaffe GJ, Grunwald JE, Daniel E, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2015 Jun;122(6):1203-11. doi: 10.1016/j.ophtha.2015.02.031. Epub 2015 Mar 29. Erratum In: Ophthalmology. 2015 Aug;122(8):1733. Cuilla, Thomas A [Corrected to Ciulla, Thomas A].

Hagstrom SA, Ying GS, Maguire MG, Martin DF; CATT Research Group; Gibson J, Lotery A, Chakravarthy U; IVAN Study Investigators. VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration. Ophthalmology. 2015 Aug;122(8):1563-8. doi: 10.1016/j.ophtha.2015.04.024. Epub 2015 May 28.

Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE, Daniel E, Jaffe GJ; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2015 Sep;122(9):1846-53.e5. doi: 10.1016/j.ophtha.2015.05.042. Epub 2015 Jul 2.

Ying GS, Maguire MG, Daniel E, Ferris FL, Jaffe GJ, Grunwald JE, Toth CA, Huang J, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology. 2015 Dec;122(12):2523-31.e1. doi: 10.1016/j.ophtha.2015.08.015. Epub 2015 Sep 15.

Ying GS, Maguire MG, Daniel E, Grunwald JE, Ahmed O, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Association between Antiplatelet or Anticoagulant Drugs and Retinal or Subretinal Hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016 Feb;123(2):352-360. doi: 10.1016/j.ophtha.2015.09.046. Epub 2015 Nov 4.

Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ, Maguire MG; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Ophthalmology. 2016 Mar;123(3):609-16. doi: 10.1016/j.ophtha.2015.10.034. Epub 2015 Dec 8.

Shah N, Maguire MG, Martin DF, Shaffer J, Ying GS, Grunwald JE, Toth CA, Jaffe GJ, Daniel E; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016 Apr;123(4):858-64. doi: 10.1016/j.ophtha.2015.11.030. Epub 2016 Jan 8.

Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology. 2016 Apr;123(4):865-75. doi: 10.1016/j.ophtha.2015.12.002. Epub 2016 Jan 9.

Zhou Q, Daniel E, Maguire MG, Grunwald JE, Martin ER, Martin DF, Ying GS; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Pseudodrusen and Incidence of Late Age-Related Macular Degeneration in Fellow Eyes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016 Jul;123(7):1530-40. doi: 10.1016/j.ophtha.2016.02.043. Epub 2016 Apr 1.

Maguire MG, Ying GS, Jaffe GJ, Toth CA, Daniel E, Grunwald J, Martin DF, Hagstrom SA; CATT Research Group. Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA Ophthalmol. 2016 Jun 1;134(6):674-81. doi: 10.1001/jamaophthalmol.2016.0669.

Other Publications:

Martin DF, Maguire MG, Fine SL. Identifying and eliminating the roadblocks to comparative-effectiveness research. N Engl J Med. 2010 Jul 8;363(2):105-7. doi: 10.1056/NEJMp1001201. Epub 2010 Jun 2. No abstract available.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Core JQ, Hua P, Daniel E, Grunwald JE, Jaffe G, Maguire MG, Ying GS; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Thiazolidinedione use and retinal fluid in the comparison of age-related macular degeneration treatments trials. Br J Ophthalmol. 2022 Apr 15:bjophthalmol-2021-320665. doi: 10.1136/bjophthalmol-2021-320665. Online ahead of print.

Core JQ, Pistilli M, Hua P, Daniel E, Grunwald JE, Toth CA, Jaffe GJ, Martin DF, Maguire MG, Ying GS; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Predominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmol Retina. 2022 Sep;6(9):771-785. doi: 10.1016/j.oret.2022.03.024. Epub 2022 Apr 9.

Kolomeyer AM, Smith E, Daniel E, Ying GS, Pan W, Pistilli M, Grunwald J, Maguire MG, Kim BJ; CATT Research Group. BETA-PERIPAPILLARY ATROPHY AND GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS. Retina. 2021 Jan 1;41(1):125-134. doi: 10.1097/IAE.00000000002825.

Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2020 May 5;5(5):CD012208. doi: 10.1002/14651858.CD012208.pub2.

Daniel E, Maguire MG, Grunwald JE, Toth CA, Jaffe GJ, Martin DF, Ying GS; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial. JAMA Ophthalmol. 2020 May 1;138(5):510-518. doi: 10.1001/jamaophthalmol.2020.0437.

Ramakrishnan MS, Yu Y, VanderBeek BL. Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial. JAMA Ophthalmol. 2020 Mar 1;138(3):237-242. doi: 10.1001/jamaophthalmol.2019.4577.

Scoles D, Ying GS, Pan W, Hua P, Grunwald JE, Daniel E, Jaffe GJ, Toth CA, Martin DF, Maguire MG; Comparison of AMD Treatments Trials Research Group. Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical Trial. JAMA Ophthalmol. 2020 Mar 1;138(3):276-284. doi: 10.1001/jamaophthalmol.2019.5831.

Bavinger JC, Ying GS, Daniel E, Grunwald JE, Maguire MG; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Association Between Cilioretinal Arteries and Advanced Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT). JAMA Ophthalmol. 2019 Nov 1;137(11):1306-1311. doi: 10.1001/jamaophthalmol.2019.3509.

Toth CA, Tai V, Pistilli M, Chiu SJ, Winter KP, Daniel E, Grunwald JE, Jaffe GJ, Martin DF, Ying GS, Farsiu S, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Distribution of OCT Features within Areas of Macular Atrophy or Scar after 2 Years of Anti-VEGF Treatment for Neovascular AMD in CATT. Ophthalmol Retina. 2019 Apr;3(4):316-325. doi: 10.1016/j.oret.2018.11.011. Epub 2018 Dec 3.

Daniel E, Ying GS, Kim BJ, Toth CA, Ferris F 3rd, Martin DF, Grunwald JE, Jaffe GJ, Dunaief JL, Pan W, Maguire MG; Comparison of Age-Related Macular Degeneration Treatments Trials. Five-Year Follow-up of Nonfibrotic Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2019 May;126(5):743-751. doi: 10.1016/j.ophtha.2018.11.020. Epub 2018 Nov 23.

Jaffe GJ, Ying GS, Toth CA, Daniel E, Grunwald JE, Martin DF, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology. 2019 Feb;126(2):252-260. doi: 10.1016/j.ophtha.2018.08.035. Epub 2018 Sep 3.

Daniel E, Pan W, Ying GS, Kim BJ, Grunwald JE, Ferris FL 3rd, Jaffe GJ, Toth CA, Martin DF, Fine SL, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials. Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Development and Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Development and Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Development and Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Development and Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Development and Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Development and Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Development and Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Development and Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Development and Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Development and Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Development and Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Development and Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Development and Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Development and Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Development and Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Development and Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Development and Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Development and Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Development and Scars in the Comparison of Age-Relat

Grunwald JE, Pistilli M, Daniel E, Ying GS, Pan W, Jaffe GJ, Toth CA, Hagstrom SA, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2017 Jan;124(1):97-104. doi: 10.1016/j.ophtha.2016.09.012. Epub 2016 Oct 27.

Responsible Party:	University of Pennsylvania
ClinicalTrials.gov Identifier:	NCT00593450 History of Changes
Other Study ID Numbers:	NEI-137
	U10EY017823 (U.S. NIH Grant/Contract)
First Posted:	January 15, 2008 Key Record Dates
Results First Posted:	August 30, 2012
Last Update Posted:	August 21, 2017
Last Verified:	July 2017
Individual Participant Data (IPD) Sharing Statem	ent:
Plan to Share IPD:	Yes
Plan Description:	Available at https://hyperprod.cceb.med.upenn.edu/catt/catt_index.php
Studies a U.S. FDA-regulated Drug Product:	Yes
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by University of Pennsylvania:

DOCKET

3/13/23, 8:48 PM

Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial - Full Text View - ClinicalTrials.gov

bevacizumab ranibizumab choroidal neovascularization

Additional relevant MeSH terms: Macular Degeneration Retinal Degeneration Retinal Diseases Eye Diseases Bevacizumab Ranibizumab Antineoplastic Agents, Immunological

Antineoplastic Agents Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors